Back Pain News and Research

Latest Back Pain News and Research

Spinal implants market to grow in the coming years: iData Research

According to a new market research report by iData Research, the leading international authority in medical device, dental and pharmaceutical market research, the U.S. market for spinal motion preservation devices is estimated to reach $2.54 billion by 2015. The global market for minimally invasive surgery (MIS) is also estimated to see double digit growth, with these two segments driving the overall market for spinal implants, MIS and VCF devices.

14 Sep 2009

Somatic Systems files financial reports with Pink Sheets

Somatic Systems, Inc. (PINKSHEETS: SMAS) announced that it has released its most recent financial reports, bringing its financial reporting status current on Pink Sheets.

14 Sep 2009

Cymbalta maintains reduction in pain for patients with chronic low back pain

New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks. In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.

11 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

Lock-Tight Facet Fixation System used performing posterior spinal fixation procedures

Spine surgeon David Raskas, M.D. at the Frontenac Surgery and Spine care Center has been performing outpatient, minimally invasive, posterior spinal fixation procedures on patients using the Lock-Tight Facet Fixation System, a unique technology that enables surgeons to fixate the facet joint without needing to perform an open procedure that usually requires fastening and fixating with pedicle screws and rods.

10 Sep 2009

Heavy school bags can cause back and spine injuries

Function and comfort over fashion is the goal this year as the kids head back to school. Starting today, the British Columbia Chiropractic Association is again launching television information to educate parents and inform them about the potential health risks an overweight back pack can cause on the early development of their children's backs.

10 Sep 2009

Yoga reduces back pain and fights depression

People with chronic low-back problems who do yoga also do better at overcoming pain and depression than people treated conventionally for back pain, a West Virginia University study funded by the National Institutes of Health shows.

5 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009

LUNA surgical procedure did not alleviate chronic pelvic pain in women

A surgical procedure known as LUNA (laparoscopic uterosacral nerve ablation) did not result in improvements in chronic pelvic pain, painful menstruation, painful sexual intercourse or quality of life when compared with laparoscopic surgery that does not interrupt pelvic nerve connections, according to a study in the September 2 issue of JAMA.

2 Sep 2009

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.

1 Sep 2009

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.

31 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

Seminar on epigenetics and applied positive psychology for health and longevity

Jennifer Mc Donell offers her audiences a unique opportunity to hear how she survived an airplane crash. Inspiring her audiences with her experience of overcoming one difficulty after another, Jennifer is in the San Francisco Bay area September/early October.

27 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

Arizona finalizes health care contract

CIGNA HealthCare announced today that it is one of four companies to have been awarded a contract to provide medical benefits to Arizona's state employees, university employees and retirees. The contract becomes effective October 1, 2009.

20 Aug 2009

Brooks Rehabilitation's new specialty clinic to provide advanced treatments for back and neck

Brooks Rehabilitation's newest specialty clinic, the Brooks Center for Back & Neck Health, offers patients advanced treatments for both acute and chronic conditions of the spine, including whiplash, lumbar stenosis, cervical or lumbar radiculopathy, cervical or lumbar instability, sciatica, TMJ, osteoarthritis, degenerative disc disease, and more. According to the National Institutes of Health, back pain is the second most common reason Americans go to the doctor (headaches are the first), and among the most common reasons for surgery. Research has demonstrated the effectiveness of physical therapy for affecting outcomes in patients with spinal conditions.

19 Aug 2009

Weight training reduces lymphedema symptoms after breast cancer surgery

Breast cancer survivors who lift weights are less likely than their non-weightlifting peers to experience worsening symptoms of lymphedema, the arm- and hand-swelling condition that plagues many women following surgery for their disease, according to new University of Pennsylvania School of Medicine research published in the August 13 issue of the New England Journal of Medicine.

18 Aug 2009

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech, Inc. today announced that a Phase III study (RIBBON 2) of Avastin (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.

18 Aug 2009